Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTORPHANOL TARTRATE vs DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, enhancing insulin secretion and decreasing glucagon release.
Management of moderate to severe pain,Preoperative medication,Supplement to balanced anesthesia,Relief of pain during labor,Off-label: Migraine headache (via intranasal route)
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Reduce risk of hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.
Oral, 5 mg dapagliflozin / 5 mg saxagliptin once daily, with or without food.
Terminal elimination half-life is 2.5-3.5 hours (mean ~3 hours) in adults; prolonged in hepatic impairment (up to 5-6 hours) and renal impairment (variable, may increase).
Dapagliflozin: terminal half-life ~12.9 hours after oral dose, supporting once-daily dosing. Saxagliptin: terminal half-life ~2.5 hours for parent drug; its active metabolite has half-life ~3.1 hours; overall DPP-4 inhibition sustained for 24 hours.
Butorphanol is extensively metabolized in the liver via hydroxylation and N-dealkylation, primarily by CYP3A4. The major metabolite is hydroxybutorphanol, which has some analgesic activity but is less potent.
Dapagliflozin: primarily metabolized via UGT1A9-glucuronidation, minor CYP-mediated metabolism (CYP3A4). Saxagliptin: extensively metabolized via CYP3A4/5 to active metabolite 5-hydroxy saxagliptin.
Primarily hepatic metabolism to inactive metabolites; renal excretion accounts for approximately 70-80% of elimination (mostly metabolites), with 15-20% via feces (biliary). Less than 5% excreted unchanged in urine.
Dapagliflozin: 75% renal (mainly as inactive glucuronide metabolite, 2% as parent drug), 21% fecal. Saxagliptin: 75% renal (metabolites, 24% as parent drug), 22% fecal. Biliary: negligible.
Approximately 80% bound to plasma proteins (mainly alpha-1-acid glycoprotein and albumin).
Dapagliflozin: ~91% bound to plasma proteins, primarily albumin. Saxagliptin: negligible binding (<10%); active metabolite similarly low.
Vd: 4-5 L/kg (range 3-6 L/kg), indicating extensive tissue distribution, including CNS.
Dapagliflozin: Vd ~118 L (1.5 L/kg) indicating extensive extravascular distribution. Saxagliptin: Vd ~1.7 L/kg, moderate tissue distribution.
Intranasal: 60-70% (range 48-80%); IM: 80-100% (complete but variable); Oral: very low (<5%) due to extensive first-pass metabolism; not used orally.
Dapagliflozin: oral bioavailability ~78%, unaffected by food. Saxagliptin: oral bioavailability ~67%, food slightly reduces rate but not extent.
No specific guidelines for dose adjustment in renal impairment; use with caution. For severe renal impairment (e GFR <30 m L/min), consider reducing dose and/or extending dosing interval due to potential accumulation of active metabolites.
e GFR ≥45 m L/min/1.73 m²: no adjustment; e GFR 30–44 m L/min/1.73 m²: not recommended; e GFR <30 m L/min/1.73 m²: contraindicated.
Child-Pugh Class A: No adjustment. Class B: Reduce dose by 25-50% and monitor for excessive sedation. Class C: Avoid use or reduce dose to 25% of normal and monitor closely.
Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not recommended (has not been studied and saxagliptin exposure is increased in severe hepatic impairment).
Weight-based: 0.01-0.02 mg/kg intravenously or intramuscularly every 3-4 hours as needed; maximum single dose 1 mg. For intranasal: 1 mg as a single dose in patients ≥18 kg (for migraine). Not recommended for PCA in children.
Not established; safety and efficacy not studied in pediatric patients.
Reduce initial dose by 50% (e.g., 0.5-1 mg IV/IM every 4-6 hours); titrate cautiously due to increased sensitivity to opioid effects and risk of respiratory depression. For intranasal, consider lower dose (0.5 mg). Monitor renal function.
No specific dose adjustment based on age; monitor renal function due to age-related decline in GFR; consider lower starting doses in elderly patients if renal function is reduced according to renal adjustment guidelines.
Concomitant use of opioids with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
None.
Respiratory depression: especially in patients with compromised respiratory function or when used with other CNS depressants,Dependence and abuse liability: Schedule IV controlled substance,Increases in intracranial pressure: may exacerbate in patients with head injury,Cardiovascular effects: may increase cardiac workload and should be avoided in acute MI,Biliary tract spasm: may cause spasm of the sphincter of Oddi,Withdrawal: may precipitate withdrawal in opioid-dependent patients if given shortly after other mu-agonists
Pancreatitis,Ketoacidosis (including euglycemic ketoacidosis),Acute kidney injury and renal impairment,Urosepsis and pyelonephritis,Hypoglycemia when used with insulin or sulfonylureas,Hypersensitivity reactions (e.g., anaphylaxis, angioedema),Severe and disabling arthralgia,Heart failure with saxagliptin
Hypersensitivity to butorphanol tartrate or any component of the formulation,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Known or suspected gastrointestinal obstruction,Patients who are physically dependent on mu-agonists due to risk of acute withdrawal
Type 1 diabetes mellitus,Diabetic ketoacidosis,Severe renal impairment (e GFR <30 m L/min/1.73 m²),History of serious hypersensitivity reaction to saxagliptin or dapagliflozin
Avoid alcohol and grapefruit juice (may increase butorphanol levels). No specific food restrictions.
No significant food interactions. Take with or without food. Avoid excessive alcohol consumption which may increase hypoglycemia risk.
Butorphanol tartrate is pregnancy category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, butorphanol administered during organogenesis produced increased fetal resorptions and decreased fetal weights at doses 3-6 times the human therapeutic dose. In the first trimester, risks cannot be ruled out. In the second and third trimesters, prolonged use may cause neonatal opioid withdrawal syndrome. Use near term may cause respiratory depression in the neonate.
Dapagliflozin: Based on animal studies, may affect renal development; human data insufficient. Avoid in second and third trimesters due to potential risk of fetal renal impairment and oligohydramnios. Saxagliptin: Animal studies show no major teratogenicity; limited human data. Overall, avoid during pregnancy unless benefit outweighs risk.
Butorphanol is excreted into human milk. The milk-to-plasma ratio (M/P) is approximately 0.7. Limited data suggest low levels; however, due to potential for serious adverse reactions in nursing infants, caution should be exercised. The manufacturer recommends avoiding use while breastfeeding.
Dapagliflozin: Excreted in animal milk; unknown in humans. Saxagliptin: Excreted in animal milk; not recommended during breastfeeding. M/P ratio not established.
Pregnancy may alter butorphanol pharmacokinetics due to increased plasma volume and enhanced clearance. However, specific dose adjustment recommendations are not established. Use lowest effective dose for shortest duration. For labor analgesia, standard IV/IM doses (1-2 mg) may be used, but monitor for maternal and neonatal respiratory depression.
No established dose adjustments; use is generally not recommended during pregnancy due to lack of safety data and potential risks. If necessary, use lowest effective dose with close monitoring.
Butorphanol is a mixed agonist-antagonist opioid; may precipitate withdrawal in opioid-dependent patients. Ceiling effect on respiratory depression. Higher risk of psychotomimetic effects (dysphoria, hallucinations) compared to morphine. Onset: 1-2 min IV, 5-10 min IM; duration 3-4 hours. Nasal spray has bioavailability ~70%.
Assess renal function before initiation; contraindicated if e GFR <30 m L/min/1.73 m2. Monitor for signs of acute pancreatitis (persistent severe abdominal pain). Avoid use with strong CYP3A4 inducers (e.g., rifampin) as saxagliptin exposure may decrease. Advise patients to temporarily discontinue during periods of reduced oral intake due to risk of ketoacidosis. Do not use in type 1 diabetes.
May cause drowsiness or dizziness; avoid driving or operating machinery.,Do not take with alcohol or other CNS depressants.,Can cause nausea, vomiting, or sweating; report severe reactions.,Use exactly as prescribed; risk of dependence with long-term use.,If you are dependent on opioids, this drug may cause withdrawal symptoms.,Notify your doctor if you have a history of head injury, asthma, or liver/kidney disease.
Take the medication once daily with or without food, preferably in the morning.,Stay well hydrated to reduce the risk of dehydration and low blood pressure.,Monitor blood sugar regularly and record results for your healthcare provider.,Seek immediate medical attention if you develop symptoms of pancreatitis (severe stomach pain with nausea/vomiting).,Report any symptoms of urinary tract infections (pain/burning with urination, fever) or genital yeast infections (itching, discharge).,Do not drink excessive alcohol as it may increase the risk of hypoglycemia.,If you skip a dose, take it as soon as you remember; do not take two doses at the same time.,Store at room temperature away from moisture and heat.
"Butorphanol, a mixed agonist-antagonist opioid, and dimenhydrinate, a histamine H1 antagonist, exhibit additive central nervous system (CNS) depression. Concurrent use increases the risk of profound sedation, respiratory depression, dizziness, and psychomotor impairment. These effects are dose-dependent and can lead to hazardous outcomes such as falls, respiratory compromise, or coma, particularly in elderly or debilitated patients."
"Concomitant use of butorphanol, a mixed agonist-antagonist opioid, with pipotiazine, a phenothiazine antipsychotic, can lead to additive central nervous system (CNS) depression, including sedation, respiratory depression, and hypotension. Pipotiazine may also potentiate the analgesic effects of butorphanol through antagonism at dopamine D2 receptors, but this combination increases the risk of extrapyramidal symptoms and neuroleptic malignant syndrome. Clinically, patients may experience excessive sedation, confusion, orthostatic hypotension, and impaired psychomotor function."
"Butorphanol, a mixed agonist-antagonist opioid, and levetiracetam, an antiepileptic, both lower the seizure threshold and can cause central nervous system (CNS) depression. Coadministration may result in additive CNS depression, leading to excessive sedation, respiratory depression, and an increased risk of seizures, especially in patients with epilepsy or head trauma. Clinically, this combination can provoke breakthrough seizures and worsen cognitive and psychomotor impairment."
"Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin levels leading to glucose-dependent insulin secretion, while Milnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may independently affect glucose homeostasis. Concurrent use could theoretically increase the risk of hypoglycemia due to additive effects on insulin secretion or glucose metabolism, although clinical data are limited. Patients should be monitored for signs of hypoglycemia, especially if also on other glucose-lowering agents."
"Tolazamide, a sulfonylurea, increases insulin secretion from pancreatic beta cells, while saxagliptin, a DPP-4 inhibitor, prolongs the action of incretin hormones (GLP-1 and GIP) to enhance glucose-dependent insulin release. When coadministered, the complementary mechanisms can lead to additive hypoglycemic effects, significantly increasing the risk of hypoglycemia, particularly in patients with renal impairment or those on irregular meal schedules."
"Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been reported to potentially reduce the systemic exposure of theophylline, a xanthine bronchodilator, likely through the induction of cytochrome P450 (CYP) 1A2, the primary enzyme responsible for theophylline metabolism. This interaction may lead to subtherapeutic theophylline concentrations, resulting in decreased bronchodilator efficacy and potential exacerbation of respiratory symptoms, particularly in patients with asthma or chronic obstructive pulmonary disease. The effect appears to be modest but may be clinically relevant in patients requiring stable theophylline levels."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTORPHANOL TARTRATE vs DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE, answered by our medical review team.
BUTORPHANOL TARTRATE is a Opioid Analgesic that works by Butorphanol tartrate is a mixed agonist-antagonist opioid analgesic that exerts its effects primarily through partial agonism at the mu-opioid receptor and full agonism at the kappa-opioid receptor. This results in analgesia with a ceiling effect for respiratory depression. It also has weak antagonistic activity at the mu receptor.. DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE is a DPP-4 Inhibitor that works by Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, enhancing insulin secretion and decreasing glucagon release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTORPHANOL TARTRATE and DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTORPHANOL TARTRATE is: 1-2 mg intravenously or intramuscularly every 3-4 hours as needed; alternatively, 1-2 mg intranasally as a single dose (for migraine, may repeat after 60 minutes). For patient-controlled analgesia (PCA): 0.5-1 mg intravenous bolus with lockout interval of 10-15 minutes. Epidural: 0.5-2 mg as a single dose.. The standard adult dose of DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE is: Oral, 5 mg dapagliflozin / 5 mg saxagliptin once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTORPHANOL TARTRATE and DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTORPHANOL TARTRATE is classified as Category C. Butorphanol tartrate is pregnancy category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, butorphanol administered during organogenesis . DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE is classified as Category A/B. Dapagliflozin: Based on animal studies, may affect renal development; human data insufficient. Avoid in second and third trimesters due to potential risk of fetal renal impairment . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.